CRISPR Therapeutics
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | 913m | <1m | 370m | 55.2m | 268m | 746m |
| % growth | (100 %) | 168055 % | (100 %) | 84762 % | (85 %) | 385 % | 179 % |
| EBITDA | (345m) | 374m | (673m) | (203m) | (515m) | (443m) | 18.1m |
| % EBITDA margin | (63582 %) | 41 % | (154395 %) | (55 %) | (934 %) | (165 %) | 2 % |
| Profit | (349m) | 378m | (650m) | (154m) | (478m) | (488m) | (266m) |
| % profit margin | (64248 %) | 41 % | (149123 %) | (42 %) | (867 %) | (183 %) | (36 %) |
| EV / revenue | 17769.8x | 3.8x | 3135.3x | 8.9x | 47.5x | 11.3x | 4.5x |
| EV / EBITDA | -27.9x | 9.2x | -2.0x | -16.2x | -5.1x | -6.8x | 186.2x |
| R&D budget | 267m | 439m | 462m | 387m | - | - | - |
| R&D % of revenue | 49161 % | 48 % | 105882 % | 105 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
€22.5m | Series A | ||
$64.0m | Series B | ||
* | €38.0m | Series B | |
| N/A | $56.0m Valuation: $626m | IPO | |
N/A | Grant | ||
* | $280m | Post IPO Equity | |
| Total Funding | €119m | ||
Recent News about CRISPR Therapeutics
EditCRISPR Therapeutics is a biotechnology company focused on developing transformative gene-based medicines for serious diseases. The company leverages CRISPR/Cas9 technology to edit genes with precision, aiming to treat conditions such as sickle cell disease, cancer, and other genetically defined diseases. CRISPR Therapeutics operates in the biopharmaceutical market, primarily serving patients with unmet medical needs. Its business model involves research and development of gene-editing therapies, followed by clinical trials and eventual commercialization. Revenue is generated through partnerships, licensing agreements, and potential future sales of approved therapies. The company targets a global market, collaborating with leading healthcare institutions and pharmaceutical companies to advance its pipeline programs.
Keywords: gene-editing, CRISPR/Cas9, biotechnology, sickle cell disease, cancer therapy, regenerative medicine, hematopoietic stem cells, in vivo editing, immuno-oncology, biopharmaceutical.
